Skip to main content

Table 1 Patients' baseline characteristics

From: Adverse events, short- and long-term outcomes of extra corporeal liver therapy in the intensive care unit: 16 years experience with MARS® in a single center

 

Overall (n = 158)

Acute-on-chronic liver failure (n = 54)

Acute liver failure (n = 32)

Post-surgery liver failure (n = 25)

Refractory pruritus (n = 35)

Drug intoxication (n = 12)

Demographics

Age (years)

54 [43–64]

56 [39–65]

58 [39–65]

58 [46–67]

48 [40–54]

51 [36–57]

Male gender (n)

99 (62.7)

41 (75.9)

18 (56.3)

19 (76.0)

13 (37.1)

8 (66.7)

BMI (kg/m2)

25 [21–28]

25 [21–29]

26 [23–29]

28 [22–29]

22 [19–24]

23 [20–25]

Severity of illness

SOFA score

8 [4–10]

9 [7–10]

8 [6–11]

8 [10–12]

3 [1–4]

11 [8–15]

Respiratory

0 [0–1]

0 [0–1]

1 [0–1]

1 [0–3]

0 [0–0]

2 [1, 2]

Cardiovascular

0 [0–0]

0 [0–0]

0 [0–3]

3 [0–4]

0 [0–0]

2 [0–4]

Hepatic

3 [2–4]

4 [4]

3 [2–4]

4 [2–4]

2 [0–3]

0 [0–2]

Coagulation

1 [0–2]

2 [1, 2]

1 [0–2]

2 [1, 2]

0 [0–1]

1 [0–2]

Neurologic

0 [0–1]

0 [0–2]

0 [0–3]

0 [0–2]

0 [0–0]

4 [4]

Renal

1 [0–2]

2 [1–3]

1 [0–4]

1 [0–1]

0 [0–0]

2 [1, 2]

Catecholamines (n)

48 (30.4)

18 (33.3)

9 (28.1)

15 (60.0)

0 (0.0)

6 (50.0)

Child Pugh score

NA

11 [10–12]

NA

NA

NA

NA

MELD score

NA

34 [28–39]

28 [22–39]

NA

NA

NA

  1. Baseline characteristics before MARS® therapy overall and in each group. Data are expressed as number (%) or median [interquartile range]
  2. BMI, Body Mass Index; NA, not applicable; SOFA, Sequential Organ Failure Assessment; MELD, model for end-stage liver disease